tapinarof
Sponsor Organon & CO. · listed as OGN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
tapinarof is a clinical-stage drug asset sponsored by Organon & CO., listed as OGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 2026 (month precision, medium confidence), tied to trial NCT05172726. The asset is in Phase 3 and currently active not recruiting, studied in Plaque Psoriasis. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-10-31
As disclosedOct 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05172726
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorOrganon and Co
Listed asOGN
Condition(s)Plaque Psoriasis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More OGN catalysts